伊沙佐米联合达雷妥尤单抗和地塞米松治疗复发/难治性多发性骨髓瘤患者的2期研究最终分析
这项单臂2期研究纳入61例复发/难治性多发性骨髓瘤患者,接受口服蛋白酶体抑制剂伊沙佐米联合达雷妥尤单抗和地塞米松(IDd)治疗。在59例可评估患者中,总缓解率为64.4%,确认的≥非常好的部分缓解率(主要终点)为30.5%。中位随访31.6个月,中位无进展生存期为16.8个月(95%CI 10.1-23.7)。
要点
- IDd方案在复发/难治性多发性骨髓瘤中总缓解率64.4%,确认的≥VGPR率30.5%。
- 中位随访31.6个月,中位无进展生存期16.8个月(95%CI 10.1-23.7)。
- ≥3级治疗中出现的不良事件发生率为54.1%,任何级别和≥3级周围神经病变分别为18.0%和1.6%。
核心结论
- IDd在复发/难治性多发性骨髓瘤患者中显示出正向的风险-获益特征,在临床相关亚组中有活性,且未发现新的安全性信号。
研究设计与样本
- 单臂2期研究(NCT03439293),纳入61例复发/难治性多发性骨髓瘤患者,既往未接受伊沙佐米/达雷妥尤单抗治疗,接受过1-3线既往治疗,接受IDd方案(28天周期)直至疾病进展或不可接受的毒性。
主要发现
- 中位年龄69岁;14.8%的患者为国际分期体系III期;14.8%的患者接受过三线既往治疗;患者接受IDd的中位周期数为16。
- 在59例可评估患者中,总缓解率为64.4%;确认的≥非常好的部分缓解率(主要终点)为30.5%。
- ≥VGPR率在以下亚组中分别为:高危细胞遗传学(n=15)26.7%,扩展高危细胞遗传学(n=24)29.2%,年龄≥75岁(n=12)16.7%,来那度胺难治(n=21)28.6%,既往接受蛋白酶体抑制剂/免疫调节剂治疗(n=58)31.0%。
- 中位随访31.6个月,中位无进展生存期为16.8个月(95%置信区间:10.1-23.7)。
- ≥3级治疗中出现的不良事件发生率为54.1%;44.3%的患者发生严重治疗中出现的不良事件;治疗中出现的不良事件导致剂量调整/减量/停药的比例分别为62.3%/36.1%/16.4%;研究期间死亡5例;任何级别和≥3级周围神经病变发生率分别为18.0%和1.6%;生活质量在整个治疗期间总体维持。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel therapies have improved outcomes for multiple myeloma (MM) patients, but most ultimately relapse, making treatment decisions for relapsed/refractory MM (RRMM) patients increasingly challenging. We report the final analysis of a single-arm, phase 2 study evaluating the oral proteasome inhibitor (PI) ixazomib combined with daratumumab and dexamethasone (IDd; NCT03439293). Sixty-one RRMM patients (ixazomib/daratumumab-naïve; 1-3 prior therapies) were enrolled to receive IDd (28-day cycles) until disease progression/unacceptable toxicity. Median age was 69 years; 14.8% of patients had International Staging System stage III disease; 14.8% had received three prior therapies. Patients received a median of 16 cycles of IDd. In 59 response-evaluable patients, the overall response rate was 64.4%; the confirmed ≥very good partial response (VGPR) rate (primary endpoint) was 30.5%. Rates of ≥VGPR in patient subgroups were: high-risk cytogenetics (n = 15, 26.7%), expanded high-risk cytogenetics (n = 24, 29.2%), aged ≥75 years (n = 12, 16.7%), lenalidomide-refractory (n = 21, 28.6%), and prior PI/IMiD therapy (n = 58, 31.0%). With a median follow-up of 31.6 months, median progression-free survival was 16.8 months (95% confidence interval: 10.1-23.7). Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 54.1% of patients; 44.3% had serious TEAEs; TEAEs led to dose modifications/reductions/discontinuations in 62.3%/36.1%/16.4%. There were five on-study deaths. Any-grade and grade ≥3 peripheral neuropathy occurred in 18.0% and 1.6% of patients. Quality of life was generally maintained throughout treatment. IDd showed a positive risk-benefit profile in RRMM patients and was active in clinically relevant subgroups with no new safety signals.
引用
- Delimpasi S, Dimopoulos MA, Straub J, et al. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma. Am J Hematol. 2024. PMID: 38856176. doi:10.1002/ajh.27382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。